Co-expression of CDX2 and MUC2 in gastric carcinomas: Correlations with clinico-pathological parameters and prognosis

Table 1 Correlation of CDX2 and MUC2 expression with clinico-pathological parameters and classifications.

Parameter	n	CDX2 positive cases (%)	MUC2 positive cases (%)
Age (yr)
≤60 yr	87	48 (55.2)	14 (16.1)
＞60 yr	103	61 (59.2)	27 (26.2)
P		0.57	0.09
Gender
Female	90	57 (63.3)	21 (23.3)
Male	100	52 (52)	20 (20)
P		0.11	0.58
WHO classification
Mucinous	4	3 (75)	4 (100)
Signet-ring cell	85	49 (57.6)	13 (15.3)
Tubular/papillary	80	47 (58.8)	20 (25)
Undifferentiated	21	10 (47.6)	4 (19)
P		0.71	0.0007
Lauren classification
Diffuse	105	61 (58.1)	19 (18.1)
Intestinal	70	40 (57.1)	18 (25.7)
Unclassified/mixed	15	8 (53.3)	4 (26.7)
P		0.94	0.43
Goseki classification
Type I	54	30 (55.6)	14 (25.9)
Type II	22	16 (72.7)	6 (27.3)
Type III	20	9 (45)	3 (15)
Type IV	94	54 (57.4)	18 (19.1)
P		0.33	0.60
pTNM stages
I	53	29 (54.7)	7 (13.2)
II	58	41 (70.7)	18 (31)
III	54	27 (50)	10 (18.5)
IV	25	12 (48)	6 (24)
P		0.09	0.13
pT stages
pT1	33	16 (48.5)	4 (12.1)
pT2	112	69 (61.6)	28 (25)
pT3	32	18 (56.3)	6 (18.8)
pT4	13	6 (45.2)	3 (23.1)
P		0.46	0.44
pN stages
pN0	52	31 (59.6)	8 (15.4)
pN1	76	48 (63.2)	21 (27.6)
pN2	52	25 (48.1)	9 (17.3)
pN3	10	5 (50)	3 (30)
P		0.36	0.28